Description
Fevipiprant research compound
Fevipiprant is an oral antagonist of the prostaglandin D2 receptor 2 (DP2, also called CRTH2), studied in allergic-inflammation research.
Product details
| Compound | Fevipiprant (QAW039) |
|---|---|
| Class | CRTH2 (DP2) receptor antagonist |
| Form | Powder |
| Strength | 5g |
| Labelling | Compound name and strength on every container |
Select your format and strength from the options above.
What research has examined
- DP2/CRTH2 signalling: eosinophil and Th2 cell research.
- Airway models: allergic inflammation research.
- Clinical research: phase 3 asthma trials that did not lead to approval.
Research interest does not establish a proven effect in humans.
Regulatory status
This compound is not an approved medicine. It is supplied only as a research chemical for laboratory use.
Storage and handling
Store sealed in a cool, dry place away from light and moisture. Use clean, dry tools when weighing.
Independent literature: search PubMed for published studies.
Related research products
SYNEPHRINE SOLUTION · Quercetin · Mucuna Pruriens Extract (20% L-Dopa) Powder · All research powders
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Reviews
There are no reviews yet.